Rigorous antibiotic stewardship in the hospitalized elderly population: saving lives and decreasing cost of inpatient care

James Mauro1, Saman Kannangara2, Joanne Peterson3, David Livert4,5 and Roman A. Tuma6,7*

1Department of Pharmacy, Easton Hospital, Easton, PA, USA; 2Department of Internal Medicine, Division of Infectious Diseases, Saint Francis Memorial Hospital, San Francisco, CA, USA; 3Department of Infection Control, Hackensack Meridian, Bayshore Medical Center, Holmdel, NJ, USA; 4Department of Medicine, Easton Hospital, Easton, PA, USA; 5Penn State University, Center Valley, PA, USA; 6Department of Internal Medicine, Hackensack Meridian, Bayshore Medical Center, Holmdel, NJ, USA; 7Department of Medicine, Hackensack Meridian School of Medicine, Nutley, NJ, USA

*Corresponding author. E-mail: roman.tuma@hmhn.org

Received 22 March 2021; accepted 7 July 2021

Background: There is limited literature evaluating the effect of antibiotic stewardship programmes (ASPs) in hospitalized geriatric patients, who are at higher risk for readmissions, developing Clostridioides difficile infection (CDI) or other adverse outcomes secondary to antibiotic treatments.

Methods: In this cohort study we compare the rates of 30 day hospital readmissions because of reinfection or development of CDI in patients 65 years and older who received ASP interventions between January and June 2017. We also assessed their mortality rates and length of stay. Patients were included if they received antibiotics for pneumonia, urinary tract infection, acute bacterial skin and skin structure infection or complicated intra-abdominal infection. The ASP team reviewed patients on antibiotics daily. ASP interventions included de-escalation of empirical or definitive therapy, change in duration of therapy or discontinuation of therapy. Treatment failure was defined as readmission because of reinfection or a new infection. A control group of patients 65 years and older who received antibiotics between January and June 2015 (pre-ASP) was analysed for comparison.

Results: We demonstrated that the 30 day hospital readmission rate for all infection types decreased during the ASP intervention period from 24.9% to 9.3%, \( P < 0.001 \). The rate of 30 day readmissions because of CDI decreased during the intervention period from 2.4% to 0.30%, \( P = 0.02 \). Mortality in the cohort that underwent ASP interventions decreased from 9.6% to 5.4%, \( P = 0.03 \). Lastly, antibiotic expenditure decreased after implementation of the ASP from $23.3 to $4.3 per adjusted patient day, in just 6 months.

Conclusions: Rigorous de-escalation and curtailing of antibiotic therapies were beneficial and without risk for the hospitalized patients 65 years and over.

Introduction

More than 50% of patients in the USA receive one or more antibiotic treatments during their hospital stay, and MDR bacteria are ever increasing.1 The 2019 Antibiotic Threats Report by the CDC stated that more than 2.8 million antibiotic resistant infections occur in the USA each year, and more than 35 000 people died as a result. In 2017, nearly 223 900 people required hospitalization in the USA because of Clostridioides difficile infections (CDIs), and at least 12 800 people died thereof. The CDC has categorized CDIs as an urgent threat.2 Most of the CDIs occur in the elderly population and cost the USA on estimated $8 billion annually.3 The elderly are the most vulnerable patient population because of immune system senescence and multiple comorbidities as well as polypharmacy, leading to multiple drug–drug interactions, and increasing the risk of MDR infections.4,5 In fact, by 2050, approximately 20% of the US population will be 65 years and older, and over the first 10 years of this decade antibiotic usage increased by 30% in the elderly.6 Therefore, geriatric patients should benefit the most from stringent antibiotic usage oversight.7–9 This is supported by the overall contribution of antibiotic stewardship programmes (ASPs) in decreasing hospital infections and MDR colonization, as well reduction of CDIs.10

The impact of ASP efforts on quality metrics remains a focus of investigations. Recent studies suggested that ASPs benefitted mortality reductions, in-hospital length of stay (LOS) reductions.
and a decrease in cost of care as accounted for by cost of antibiotic consumption.\textsuperscript{11–13} The effect of ASPs on readmission rates has not been frequently reported and was variable, ranging from favourable, to having no impact, to correlating with an increase in readmission rates.\textsuperscript{11–14}

In this study, we investigated the impact of a rigorous ASP on quality metrics in a hospitalized, elderly population. The primary objective was to determine if our ASP decreased 30-day hospital readmissions secondary to re-infection, including readmissions because of CDIs. The secondary objective was to determine if the patient-specific infection diagnosis of pneumonia (PNA), urinary tract infection (UTI), acute bacterial skin and skin structure infection (ABSSSI) or complicated intra-abdominal infection (cIAI) influenced the effectiveness of the ASP interventions in preventing hospital readmissions. Moreover, would these efforts decrease LOS and in-hospital mortality, as well as the cost of hospitalization because of a reduction in antibiotic expenditure?

**Methods**

This cohort study represents a single centre, retrospective chart review in a 256 bed teaching hospital in the USA. The ASP intervention group consisted of adult patients \( \geq 65 \) years old, who received ASP interventions between January and June 2017. The control group consisted of adult patients \( \geq 65 \) years old, who received antibiotic therapies between January and June 2015 (pre-ASP era).

Inclusion criteria included adult patients \( \geq 65 \) years old, who received antibiotics during inpatient hospital stay and carried a diagnosis of PNA, UTI, ABSSSI or cIAI. Exclusion criteria included patients who died or transitioned to hospice care as well as non-acceptance of ASP recommendations in the intervention group. Statistical analyses employed \( t \)-test and \( \chi^2 \) statistics as well as Mann–Whitney \( U \) test where appropriate. Two-tailed \( p \)-values less than 0.05 were considered statistically significant. We applied the Statistical Package for the Social Sciences (SPSS) Version 20.0 (2012).

All antibiotic therapy recommendations were based on clinical practice guidelines of IDSA, the American Thoracic Society and the Surgical Infection Society, and were implemented during the first 24–48 h of the initiation of antibiotic regimens. The following ASP interventions were conducted: (i) de-escalation or escalation of empirical or definitive therapy; (ii) change in duration of therapy; and (iii) discontinuation of therapy. Infectious diseases diagnoses were reviewed and appropriateness of antibiotics as well as dose adjustments were addressed within categories (i)–(iii). The ASP team consisted of a clinical pharmacist, an infectious diseases physician and a clinical nurse. Specifically, on a daily basis the clinical pharmacist, after consulting with the ASP infectious disease specialist, called the respective attending physicians and conveyed antibiotic treatment recommendations. The following day, the patient’s medical records were reviewed to assess adherence to recommendations. If recommendations were not followed, the ASP conducted a re-review, and the infectious disease specialist personally contacted the antibiotic prescriber attending for discussion and follow through. Daily review of preliminary and final microbiological culture results was part of the decision-making but pending results did not preclude intervention recommendations. Education of the medical staff was an integral part of the ‘buy-in’ and was conducted by one-on-one phone conversations between the clinical pharmacist or infectious disease specialist and the antibiotic prescribing physician. Of note, our actual ASP was started in the last quarter of 2015. Otherwise, we did not identify any changes in the clinical decision-making systems supporting antibiotic prescribing, such as our electronic healthcare record, nor were approval processes for prescribing antibiotics changed for the control and intervention group, beyond the ASP recommendations. General medical management principles, including infectious diseases consulting practices and readmission initiatives, as well as the overall demographics of the admitted elderly patients did not undergo any apparent changes and were comparable during the control and intervention periods of this study. Our readmission rates reflected returns to the hospital within 30 days after initial discharge because of re-infection or new infection. Readmissions secondary to other comorbidities, accounting for the overall readmission rate, were not included. The mortality rates represented in-hospital mortalities.

**Ethics**

This study’s protocol was approved by the Institutional Review Board (IRB) of Easton Hospital, Easton, PA, USA. All personal information of patients was maintained confidentially. Because we used retrospective data retrieved from medical records based on IRB permission, patients’ informed consent was not obtained.

**Results**

Table 1 outlines the demographics and infection types as well as the overall utilization of antibiotics and their cost in the ASP-intervention group (pre- and post-review) and the historical control group. Antibiotics utilized in less than five patient regimens were grouped into the ‘other’ category. Overall adherence to ASP recommendations was \( > 95 \). Of note, the majority of ASP interventions were de-escalations (62\%) and discontinuations (24\%) (Table 2). These interventions resulted in a remarkable decrease of broad-spectrum antibiotic therapies as well as glycopeptide utilization (Table 1). Conversely, first-generation cephalosporin and penicillin as well as aminopenicillin antibiotics were not administered in the intervention group prior to ASP recommendation nor in the historical control group (Table 1). Antibiotic utilization by infection type is detailed in Table 3.

Our analysis showed a significant reduction in overall readmission rates for patients whose antibiotic therapies underwent ASP interventions as compared with the historical control cohort: 29 versus 135 patients (9\% versus 24.9\%; \( P < 0.001 \)) (Figure 1).

The readmission rates for patients diagnosed with PNA and ABSSSI were significantly lower in the ASP-intervention group as compared with the historical control group: 11 versus 77 patients (8.5\% versus 28.9\%; \( P < 0.001 \)) and 1 versus 19 (3.8\% versus 22.8\%; \( P = 0.03 \)), respectively. We identified a difference in the readmission rates for UTI and cIAI between the ASP-intervention cohort and the historical control group as well. However, the decrease did not reach statistical significance: 13 versus 27 patients (13\% versus 20.3\%; \( P = 0.125 \)) and 1 versus 14 (7.1\% versus 22.8\%; \( P = 0.187 \)), respectively (Figure 2).

Of note, the 30 day readmission rate was significantly lower for patients diagnosed with CDI in the ASP-intervention group as compared with the historical control group, 1 versus 13 (0.3\% versus 2.4\%; \( P = 0.025 \)).

ASP interventions did not lead to higher in-hospital mortalities as compared with the control cohort. To the contrary, our analysis suggested that the mortality for the intervention group decreased significantly to 1 versus 13 (0.3\% versus 9.6\%; \( P = 0.033 \)).

We did not demonstrate a difference in the LOS between the ASP-intervention and historical control groups, 7.26 days versus 7.5 days (\( P = 0.21 \)).

Our ASP programme resulted in a dramatic reduction in antibiotic expenditure. Over a 6 month period, between January and June
2017, the expenditure per adjusted patient days (APD) decreased to $4.37 as compared with $23.33 for the historical control group. This translated into a total cost for antibiotics during the control period of $379,643 as compared with $67,721 during the ASP-intervention period. The discrepancy in cost suggests the uninhibited administration of antibiotics in the historical control group as compared with the antibiotic usage after ASP intervention (Table 1).

**Discussion**

Studying the association between ASP efforts and patient outcomes is of great importance as it increases our understanding of how ASPs contribute to the patient’s overall quality of care. We show that a stringent ASP can be safely implemented in an elderly hospitalized patient population without discernible adverse outcomes. Specifically, rigorous ASP interventions in patients older than 65 years correlated with an overall reduction in 30-day readmissions in patients for all studied infection types. This is remarkable as several past studies did not find an association between readmissions and ASPs. Moreover, Ritchie et al. suggested that antibiotic treatment recommendations may actually have contributed to an increase in readmissions while it decreased the LOS in patients with cellulitis. We cannot readily explain this difference as the correlations between different outcome measures are complex and vary amongst hospitals and patient populations. However, Chopra et al. showed a correlation between decreasing CDIs and decreasing readmission rates, which may have contributed to the decrease in readmissions in our study. Moreover, our ASP efforts did not affect the LOS of our intervention group. This could have furthermore decreased readmission rates, as we know that a decrease in LOS may adversely affect readmissions.

Interestingly, we observed a statistically significant decrease in patient mortality in patients whose antibiotic treatments were

---

| Table 1. Patient characteristics |
|---------------------------------|
| Characteristic                  | Control (n = 544) | ASP intervention (n = 297) | P value |
| Age, years, mean                | 79.5             | 80.2                       | 0.26    |
| Male gender, n (%)              | 239 (44.0)       | 138 (46.6)                 | 0.48    |
| Infection type, n (%)           |                  |                            |         |
| PNA                              | 268 (49.4)       | 135 (45.5)                 | 0.27    |
| UTI                              | 132 (24.4)       | 100 (33.7)                 | 0.005   |
| ABSSSI                           | 83 (15.3)        | 35 (11.8)                  | 0.026   |
| cIAI                             | 61 (11.3)        | 14 (4.7)                   | 0.001   |
| othera                          | 13 (2.4)         | 13 (4.4)                   | 0.111   |
| Antimicrobial therapies, n (%)b |                  |                            |         |
| carbapenem                      | 80 (9.2)         | 12 (4.0)                   | 1 (0.5) |
| penicillin (antipseudomonal)    | 161 (18.6)       | 72 (24.1)                  | 8 (3.7) |
| cephalosporin (fourth generation)| 91 (10.5)       | 35 (11.7)                  | 8 (3.7) |
| fluoroquinolone                 | 116 (13.4)       | 6 (2.0)                    | 12 (5.6) |
| cephalosporin (third generation)| 71 (8.2)         | 43 (14.4)                  | 49 (22.9)|
| penicillin (aminopenicillin)    | 0 (0.0)          | 2 (0.7)                    | 35 (16.4)|
| cephalosporin (fifth generation)| 10 (1.2)         | 0 (0.0)                    | 0 (0.0) |
| monobactam                      | 28 (3.2)         | 4 (1.3)                    | 0 (0.0) |
| cephalosporin (first generation)| 0 (0.0)          | 0 (0.0)                    | 52 (24.3)|
| miscellaneousc                  | 27 (3.1)         | 13 (4.3)                   | 22 (10.3)|
| glycopeptide                    | 253 (29.2)       | 93 (31.1)                  | 17 (7.9) |
| oxazolidinone                   | 9 (1.0)          | 2 (0.7)                    | 2 (0.9) |
| otherd                          | 20 (2.3)         | 6 (2.0)                    | 8 (3.7) |
| Antimicrobial expenditure, $     |                  |                            |         |
| total                           | 379,643          | 67,721                     |         |
| cost/APD                        | 23.33            | 4.37                       |         |

aSepsis, fever (neutropenic, post-operative, unknown origin), osteomyelitis, prosthetic joint infection, leucocytosis.

bAntimicrobials used as monotherapy or in combination with other agents.

cFosfomycin, metronidazole, nitrofurantoin, trimethoprim/sulfamethoxazole.

dAzithromycin, clindamycin, daptomycin, doxycycline, fluconazole, micasfungin, tigecycline.

---

2017, the expenditure per adjusted patient days (APD) decreased to $4.37 as compared with $23.33 for the historical control group. This translated into a total cost for antibiotics during the control period of $379,643 as compared with $67,721 during the ASP-intervention period. The discrepancy in cost suggests the uninhibited administration of antibiotics in the historical control group as compared with the antibiotic usage after ASP intervention (Table 1).

---

**Table 2. Type of ASP intervention**

| Intervention type | n (%) |
|-------------------|-------|
| De-escalation     | 185 (62.3) |
| Discontinuation   | 71 (23.9) |
| Duration          | 30 (10.1) |
| Escalation        | 12 (4.0)  |
### Table 3. Antimicrobial usage by infection type

| Infection type/Antimicrobial | Control | ASP intervention |  |
|------------------------------|---------|------------------|---|
|                              |         | pre-review       | post-review |
| **PNA, n (%)**               |         |                 |             |
| carbenem                     | 35 (8.1) | 3 (2.4)          | 1 (1.1)     |
| penicillin (antipseudomonal) | 83 (19.3)| 42 (33.6)        | 3 (3.4)     |
| cephalosporin (fourth generation) | 27 (6.3) | 13 (10.4)        | 5 (5.6)     |
| fluoroquinolone              | 53 (12.3)| 2 (1.6)          | 5 (5.6)     |
| cephalosporin (third generation) | 53 (12.3)| 6 (3.2)          | 32 (35.9)   |
| penicillin (aminopenicillin) | 3 (0.7) | 0 (0.0)          | 15 (16.8)   |
| cephalosporin (fifth generation) | 1 (0.2) | 0 (0.0)          | 0 (0.0)     |
| monobactam                   | 17 (4.0) | 4 (3.2)          | 0 (0.0)     |
| cephalosporin (first generation) | 0 (0.0) | 1 (0.8)          | 5 (5.6)     |
| miscellaneous<sup>b</sup>    | 1 (0.2) | 9 (7.2)          | 13 (14.6)   |
| glycopeptide                 | 146 (34.0)| 46 (36.8)       | 5 (5.6)     |
| oxazolidinone                | 2 (0.5) | 0 (0.0)          | 0 (0.0)     |
| other<sup>c</sup>            | 9 (2.1) | 2 (1.6)          | 5 (5.6)     |
| **UTI, n (%)**               |         |                 |             |
| carbenem                     | 19 (10.5)| 7 (9.2)          | 0 (0.0)     |
| penicillin (antipseudomonal) | 30 (16.6)| 6 (7.9)          | 0 (0.0)     |
| cephalosporin (fourth generation) | 17 (9.4)| 8 (10.5)        | 1 (1.6)     |
| fluoroquinolone              | 29 (16.0)| 3 (3.9)          | 4 (6.3)     |
| cephalosporin (third generation) | 35 (19.3)| 39 (51.3)      | 3 (4.7)     |
| penicillin (aminopenicillin) | 0 (0.0)  | 1 (1.3)          | 10 (15.6)   |
| cephalosporin (fifth generation) | 0 (0.0) | 0 (0.0)          | 0 (0.0)     |
| monobactam                   | 6 (3.3)  | 0 (0.0)          | 0 (0.0)     |
| cephalosporin (first generation) | 0 (0.0) | 0 (0.0)          | 38 (59.4)   |
| miscellaneous<sup>b</sup>    | 0 (0.0)  | 1 (1.3)          | 4 (6.3)     |
| glycopeptide                 | 41 (22.7) | 8 (10.5)        | 2 (3.1)     |
| oxazolidinone                | 4 (2.2) | 2 (2.6)          | 1 (1.6)     |
| other<sup>c</sup>            | 3 (1.7)  | 1 (1.3)          | 1 (1.6)     |
| **ABSSSI, n (%)**            |         |                 |             |
| carbenem                     | 12 (9.2) | 1 (2.0)          | 0 (0.0)     |
| penicillin (antipseudomonal) | 26 (20.0)| 11 (22.0)        | 2 (7.4)     |
| cephalosporin (fourth generation) | 6 (4.6) | 7 (14.0)        | 1 (3.7)     |
| fluoroquinolone              | 10 (7.7) | 1 (2.0)          | 2 (7.4)     |
| cephalosporin (third generation) | 1 (0.8) | 2 (4.0)          | 4 (14.8)    |
| penicillin (aminopenicillin) | 1 (0.8)  | 3 (6.0)          | 3 (11.1)    |
| cephalosporin (fifth generation) | 9 (6.9) | 0 (0.0)          | 0 (0.0)     |
| monobactam                   | 2 (1.5)  | 0 (0.0)          | 0 (0.0)     |
| cephalosporin (first generation) | 0 (0.0) | 0 (0.0)          | 7 (25.9)    |
| miscellaneous<sup>b</sup>    | 0 (0.0)  | 2 (4.0)          | 1 (3.7)     |
| glycopeptide                 | 58 (44.6)| 21 (42.0)        | 5 (18.5)    |
| oxazolidinone                | 1 (0.8) | 0 (0.0)          | 0 (0.0)     |
| other<sup>c</sup>            | 4 (3.1) | 2 (4.0)          | 2 (7.4)     |
| **cIAI, n (%)**              |         |                 |             |
| carbenem                     | 12 (11.5)| 1 (11.1)         | 0 (0.0)     |
| penicillin (antipseudomonal) | 20 (19.2)| 4 (44.4)         | 2 (22.2)    |
| cephalosporin (fourth generation) | 2 (1.9) | 1 (11.1)        | 0 (0.0)     |
| fluoroquinolone              | 22 (21.1)| 0 (0.0)          | 0 (0.0)     |
| cephalosporin (third generation) | 1 (1.0) | 0 (0.0)          | 3 (33.3)    |
| penicillin (aminopenicillin) | 0 (0.0)  | 0 (0.0)          | 1 (11.1)    |
| cephalosporin (fifth generation) | 0 (0.0) | 0 (0.0)          | 0 (0.0)     |
| monobactam                   | 2 (1.9)  | 0 (0.0)          | 0 (0.0)     |

Continued
monitored by the ASP, underscoring the safety of the program.\textsuperscript{21–23}

This is an important finding as narrowing and discontinuation of antibiotic therapies can be challenging because of a fear for the ‘wellbeing of patients’, particularly in a vulnerable, elderly population. Ritchie \textit{et al.},\textsuperscript{13} similarly, demonstrated a decrease in mortality in their patient population that underwent antibiotic treatment recommendations. Additional studies underscore the safety of ASPs by suggesting no negative effects on mortality.\textsuperscript{12,24–26}

Finally, we demonstrate a significant decrease in antibiotic expenditure per APD. Substantial cost savings have been demonstrated by other investigators and underscore the cost-saving opportunities that ASPs offer.\textsuperscript{11,13,19} Indeed, our savings formed the basis to employ our Clinical Pharmacist permanently, full-time. In the current healthcare environment, convincing healthcare administrators to invest in additional full-time equivalents requires solid evidence of their contribution to safety and quality, but also demonstration of financial viability.

We have identified limitations to our study as the levofloxacin usage differed significantly between the historical control group and the intervention group. FDA warnings against the use of fluoroquinolone antibiotics likely contributed to this difference.\textsuperscript{27} We also noticed an overall greater administration of broad-spectrum antibiotics in the historical control group. The greater number of cIAI in our historical control group could have contributed to this difference. Most importantly, we launched our ASP in the fourth quarter of 2015. Therefore, antibiotic treatment interventions were conducted during the time period between the historical control group and the ASP intervention group. This undoubtedly contributed to the greater usage of narrow-spectrum antibiotics and decreased utilization of fluoroquinolones in the ASP intervention group. Although this may have accentuated our results it should not have diminished the effect of the ASP on the studied quality metrics. Further limitations of cohort studies include an inherent selective bias: more seriously ill patients receive broader antibiotic therapies as compared with less ill individuals.

### Table 3. \textit{Continued}

| Infection type/Antimicrobial | Control                  | ASP intervention |
|------------------------------|--------------------------|------------------|
|                              | pre-review               | post-review      |
| cephalosporin (first generation) | 0 (0.0)                  | 0 (0.0)          |
| miscellaneous\textsuperscript{b} | 25 (24.0)              | 1 (11.1)         |
| glycopeptide                 | 14 (13.5)                | 2 (22.2)         |
| oxazolidinone                | 2 (1.9)                  | 0 (0.0)          |
| other\textsuperscript{c}     | 4 (3.8)                  | 0 (0.0)          |
| Other, \(n\) (%)\textsuperscript{d} | \(2 (10.0)\)         | 0 (0.0)          |
| carbenem                    | 0 (0.0)                  | 0 (0.0)          |
| penicillin (antipseudomonal) | 0 (0.0)                  | 0 (0.0)          |
| cephalosporin (fourth generation) | 5 (25.0)               | 9 (23.1)         |
| fluoroquinolone             | 2 (10.0)                 | 1 (2.6)          |
| penicillin (aminopenicillin) | 1 (5.0)                  | 1 (2.6)          |
| cephalosporin (fifth generation) | 0 (0.0)               | 0 (0.0)          |
| monobactam                  | 1 (5.0)                  | 0 (0.0)          |
| cephalosporin (first generation) | 0 (0.0)               | 0 (0.0)          |
| miscellaneous\textsuperscript{b} | 0 (0.0)               | 0 (0.0)          |
| glycopeptide                | 7 (35.0)                 | 15 (38.5)        |
| oxazolidinone               | 0 (0.0)                  | 5 (20.0)         |
| other\textsuperscript{c}    | 0 (0.0)                  | 0 (0.0)          |

\textsuperscript{a}Antimicrobials used as monotherapy or in combination with other agents.
\textsuperscript{b}Fosfomycin, metronidazole, nitrofurantoin, trimethoprim/sulfamethoxazole.
\textsuperscript{c}Azithromycin, clindamycin, daptomycin, doxycycline, fluconazole, micafungin, tigecycline.
\textsuperscript{d}Sepsis, fever (neutropenic, post-operative, unknown origin), osteomyelitis, prosthetic joint infection, leucocytosis.

\textbf{Figure 1.} Overall rate of 30 day readmission.
We did not apply a severity score to the intervention and control group confounding the possibility of a bias.

Despite the apparent limiting factors of this study, or results suggest that rigorous ASPs can be safely and successfully implemented in elderly, hospitalized patients.

Future research needs to be directed towards ensuring standardization and unequivocal reproducibility of ASP interventions to optimize patient outcomes and allow comparisons between different healthcare settings.

Funding
This study was carried out as part of our routine work.

Transparency declarations
None to declare.

Author contributions
R.A.T., J.M. and S.K. collected the data for this study. R.A.T., J.M., S.K. and D.L. summarized the data. R.A.T. wrote the first draft of this manuscript. All authors, including R.A.T., J.M., S.K., D.L. and J.P. contributed to the interpretation of the findings, critically reviewed subsequent revisions and approved the final version.

References
1. Baggs J, Fridkin SK, Pollack LA et al. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med 2016;176:1639–48.
2. CDC. Antibiotic Resistance Threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
3. McGlone SM, Bailey RR, Zimmer SM et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012;18:282–9.
4. Castle SC. Impact of age-related immune dysfunction on risk of infections. Z Gerontol Geriatr 2000;33:341–9.
5. van Duin D, Mohanty S, Thomas V et al. Age-associated defect in human TLR-1/2 function. J Immunol 2007;178:970–5.
6. Lee CG, Reveles KR, Attridge RT et al. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med 2014;12:96.
7. Feazal LM, Malhotra A, Perencevich EN et al. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1748–54.
8. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. In: HCUP Statistical Brief #124. US Agency for Healthcare Research and Quality, 2012.
9. Malani AN, Richards PG, Kapila S et al. Clinical and economic outcomes from a community hospital’s antimicrobial stewardship program. Am J Infect Control 2013;41:145–8.
10. Baur D, Gladstone BP, Burkert F et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017;17:990–1001.
11. Boyles TH, Whitelaw A, Bambord C et al. Antibiotic stewardship ward rounds and a dedicated prescription chart reduce antibiotic consumption and pharmacy costs without affecting inpatient mortality or readmission rates. PLoS One 2013;8:e79747.
12. Wathne JS, Harthug S, Kleppe LKS et al. The association between adherence to national antibiotic guidelines and mortality, readmission and length of stay in hospital inpatients: results from a Norwegian multicentre, observational cohort study. Antimicrob Resist Infect Control 2019;8:63.
13. Ritchie SR, Cutfield T, Lee A et al. The impact of the Auckland cellulitis pathway on length of hospital stay, mortality readmission rate, and antibiotic stewardship. Clin Inf Dis 2021;doi:10.1093/cid/ciab181.
14. Schuts EC, Hulscher MEJL, Mouton JW et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis 2016;16:847–56.
15. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2020. https://www.R-project.org/.
16 Mendez R, Reyes S, Martinez R et al. Economic evaluation of adherence to treatment guidelines in nonintensive pneumonia. Eur Respir J 2007; 29: 751–6.
17 Reyes CS, Martinez TR, C, Romero, MJ et al. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Resp Med 2007; 101: 1909–15.
18 Fanning M, McKeen M, Seymour K et al. Adherence to guideline-based antibiotic treatment for acute exacerbations of chronic obstructive pulmonary disease in an Australian tertiary hospital. Intern Med J 2014; 44: 903–10.
19 Lingsma HF, Bottle A, Middleton S et al. Evaluation of hospital outcomes: the relation between length-of-stay, readmission, and mortality in a large international administrative database. BMC Health Serv Res 2018; 18: 116.
20 Chopra T, Neelakanta A, Dombeck C et al. Burden of Clostridium difficile infection on hospital readmissions and its potential impact under the Hospital Readmission Reduction Program. Am J Infect Control 2015; 43: 314–7.
21 Schmitt S, McQuillen DP, Nahass R et al. Infectious diseases specialty intervention is associated with decreased mortality and lower costs. Clin Infect Dis 2014; 58: 22–8.
22 Buckel WR, Sytenehjem E, Sorensen J et al. Broad-versus narrow-spectrum oral antibiotic transition and outcomes in healthcare associated pneumonia. Ann Am Thorac Soc 2017; 14: 200–5.
23 Ramirez JA, Srinath L, Ahkee S et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6.
24 Arnold FW, LaJoie AS, Brock GN et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009; 169: 1515–24.
25 Asadi I, Eurich DT, Gamble JM et al. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Clin Microbiol Infect 2013; 19: 257–64.
26 Egelund GB, Jensen AV, Anderson SB et al. Penicillin treatment for patients with community-acquired pneumonia in Denmark: a retrospective cohort study. BMC Pulm Med 2017; 17: 66.
27 US FDA. Drug Safety Communication: FDA Advises Restricting Fluoroquinolone Antibiotic Use for Certain Uncomplicated Infections; Warns About Disabling Side Effects That Can Occur Together 5-12-2016. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain.